Kamala Arumalla

Dr. Kamala Arumalla


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MVMaria Vaida
Maria Vaida
KAKamala Arumalla
Kamala Arumalla
PTPavan Kumar Tatikonda
Pavan Kumar Tatikonda
Bharadwaj PopuriBharadwaj Popuri
Bharadwaj Popuri
RBRashid Ahmed Bux
Rashid Ahmed Bux
WFW. Randolph Ford
W. Randolph Ford
Breast cancer remains a major public health concern, and early detection is crucial for improving survival rates. Metabolomics offers the potential to develop non-invasive screening and diagnostic tools based on metabolic biomarkers. However, the inherent complexity of metabolomic datasets and the high dimensionality of biomarkers complicates the identification of diagnostically relevant features, with multiple studies demonstrating limited consensus on the specific metabolites involved. Unlike previous studies that rely on singular feature selection techniques such as Partial Least Square (PLS) or LASSO regression, this research combines supervised and unsupervised machine learning methods with random sampling strategies, offering a more robust and interpretable approach to feature selection. This study aimed to identify a parsimonious and robust set of biomarkers for breast cancer diagnosis using metabolomics data. Plasma samples from 185 breast cancer patients and 53 controls (from the Cooperative Human Tissue Network, USA) were analyzed. This study also overcomes the common issue of dataset imbalance by using propensity score matching (PSM), which ensures reliable comparisons between cancer and control groups. We employed Univariate Naïve Bayes, L2-regularized Support Vector Classifier (SVC), Principal Component Analysis (PCA), and feature engineering techniques to refine and select the most informative features. Our best-performing feature set comprised 11 biomarkers, including 9 metabolites (SM(OH) C22:2, SM C18:0, C0, C3OH, C14:2OH, C16:2OH, LysoPC a C18:1, PC aa C36:0 and Asparagine), a metabolite ratio (Kynurenine-to-Tryptophan), and 1 demographic variable (Age), achieving an area under the ROC curve (AUC) of 98%. These results demonstrate the potential for a robust, cost-effective, and non-invasive breast cancer screening and diagnostic tool, offering significant clinical value for early detection and personalized patient management.

15 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MVMaria Vaida
Maria Vaida
KAKamala Arumalla
Kamala Arumalla
PTPavan Kumar Tatikonda
Pavan Kumar Tatikonda
Bharadwaj PopuriBharadwaj Popuri
Bharadwaj Popuri
RBRashid Ahmed Bux
Rashid Ahmed Bux
WFW. Randolph Ford
W. Randolph Ford
Breast cancer remains a major public health concern, and early detection can result in more treatment options, which are crucial for improving survival rates. Metabolomics offers the potential to develop blood-based screening and diagnostics tools that are less invasive and more cost-effective. However, the inherent complexity of metabolomic datasets makes identifying the most diagnostically relevant biomarkers a difficult task, with multiple studies demonstrating lim-ited agreement on the specific metabolites and pathways involved. This study aims to identify a set of biomarkers for early diagnosis of breast cancer using metabolomics data. Plasma samples from 185 breast cancer patients and 53 controls (CHTN) were analyzed. We utilized univariate Naïve Bayes, L2-regularized Support Vector Machines, and Principal Component Analysis (PCA), along with feature engineering techniques, to select the most informative features. Multiple ma-chine learning models, including Support Vector Machines, Multidimensional Scaling, Logistic Regression, and Ensemble Learning were utilized for classification. The best-performing feature set comprised 4 biomarkers and 2 demographic variables, achieving an accuracy of 98%, demon-strating the potential for a robust, cost-effective, non-invasive breast cancer screening and diagnostic tool.

21 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KAKamala Arumalla
Kamala Arumalla
JHJean-Francois Haince
Jean-Francois Haince
RBRashid Ahmed Bux
Rashid Ahmed Bux
GHGUOYU HUANG
GUOYU HUANG
PTParamjit S Tappia
Paramjit S Tappia
MVMaria Vaida
Maria Vaida
Breast cancer is a global concern as a leading cause of death for women. Early and precise diagnosis can be vital in handling the disease efficiently. Breast cancer subtyping based on estrogen receptor (ER) status is crucial for determining prognosis and treatment. This study uses metabolomics data from plasma samples to detect metabolite biomarkers that could distinguish ER-positive from ER-negative breast cancers in a non-invasive manner. The dataset includes demographic information, ER status, and metabolite levels from 188 breast cancer patients and 73 healthy controls. Supervised, unsupervised, and ensemble machine learning (ML) algorithms were applied to identify key metabolites associated with ER status, including Support Vector Machines (SVM), Multidimensional Scaling (MS), Logistic Regression (LR), and Ensemble learning. The most informative feature set, containing 28 biomarkers and two demographic factors, achieved an impressive 96% accuracy and an area under the curve (AUC) of 93% using the Logistic Regression model. These results suggest that ML has great promise for identifying specific metabolites linked to ER expression, paving the development of a novel analytical tool that can minimize current lab challenges such as analytical sample handling, subjective results interpretation, biological heterogeneity of the tumor in a non-invasive and efficient manner aiding in more precise diagnosis of breast cancer.